合寶丰年(08406.HK)延遲刊發年度業績
格隆匯3月18日丨合寶丰年(08406.HK)公佈,公司已獲悉,因新型冠狀病毒(COVID-19)疫症爆發,各地實施旅遊限制及強制醫學監察措施,中國(集團主要營業地點)的相關實地審核工作受到不利影響。因此,儘管集團正編制截至2019年12月31日止年度的財務業績,但公司預期將延遲根據香港聯合交易所有限公司GEM上市規則規定發佈該年度的經審核財務業績及寄發年度報告。
然而,為確保公司股東及有意投資者瞭解集團財務表現及狀況,公司計劃於2020年3月30日發佈該年度的未經審核初步財務業績連同2018年同期的經審核比較數字。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.